Floris Groenendaal/LinkedIn
Nov 21, 2025, 08:54
Floris Groenendaal: Periventricular Hemorrhagic Infarction in Term Neonates
Floris Groenendaal, Pediatrician-Neonatologist at University of Utrecht, shared on LinkedIn:
”Our manuscript on term infants with periventricular haemorrhagic infarction has been published.
Our main findings are:
- Seizures around the second day were the most commonly presenting symptom.
- Prothrombotic genetic mutations are potential risk factors in term- born neonates.
- The majority of lesions occurred in the caudate vein territory.
- Most infants showed normal early cognitive outcomes, but motor impairment was significantly more common
So long-term neurodevelopmental follow-up is definitely needed.”
Read the full article here.
Article: Neonates born at term with periventricular haemorrhagic infarction: Risk factors and clinical presentation
Authors: Aleksandra Zaykova, Jeroen Dudink, Floris Groenendaal, Maarten H Lequin, Manon J N L Benders, Maria Luisa Tataranno, Elise Roze
Stay updated on all scientific advances with Hemostasis Today.
-
Mar 13, 2026, 22:57Robert Hamilton: The Reality of Stroke Care and Why 81.6% Should be a Wake-Up call
-
Mar 13, 2026, 22:05Christoph B. Olivier: Annabel Hölzle Shared Critical Findings on HALT After TAVR
-
Mar 13, 2026, 21:29Timothy Glidewell: Genetic Signals of Platelet and Clotting Pathways in Cryptogenic Stroke
-
Mar 13, 2026, 21:19New Canadian Insights on Switching to Longer-Acting Therapy for Hemophilia A – WFH
-
Mar 13, 2026, 21:01Leonardo Roever: Brain Age as a Biomarker of Neuroplasticity and Motor Recovery After Stroke
-
Mar 13, 2026, 20:50William Tembo: Understanding Stroke Through Landmark Clinical Trials
-
Mar 13, 2026, 20:35Jessica Garcia: New Evidence on Thrombin Generation Patterns in Children with Hemophilia A
-
Mar 13, 2026, 20:11Christoph B. Olivier: New Research from Marius Wessinger on Predicting Therapy Success After Pulmonary Embolism
-
Mar 13, 2026, 19:53Wolfgang Miesbach Announces the New English Edition of “Gene Therapy Concepts in the Treatment of Haemophilia”